Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07070674Phase 1Recruiting

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

Role: lead

NCT07083193Phase 1Recruiting

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

Role: lead

NCT06972888Phase 2Completed

A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

Role: lead

All 3 trials loaded